| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581709 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 24 Pages |
Abstract
The increased risk of CVD observed in this real-world analysis of patients with CML underscores the importance of current National Comprehensive Cancer Network recommendations to consider cardiovascular risk when selecting tyrosine kinase inhibitors.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Anna D. Coutinho, Dinara Makenbaeva, Eileen Farrelly, Pamela B. Landsman-Blumberg, Daniel Lenihan,